NO20053792L - Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander - Google Patents
Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 liganderInfo
- Publication number
- NO20053792L NO20053792L NO20053792A NO20053792A NO20053792L NO 20053792 L NO20053792 L NO 20053792L NO 20053792 A NO20053792 A NO 20053792A NO 20053792 A NO20053792 A NO 20053792A NO 20053792 L NO20053792 L NO 20053792L
- Authority
- NO
- Norway
- Prior art keywords
- sulfonylindazoles
- heterocycly
- hydroxytryptamine
- ligands
- receptor
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44761303P | 2003-02-14 | 2003-02-14 | |
| PCT/US2004/003926 WO2004074243A2 (en) | 2003-02-14 | 2004-02-10 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20053792L true NO20053792L (no) | 2005-08-10 |
Family
ID=32908471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053792A NO20053792L (no) | 2003-02-14 | 2005-08-10 | Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7238696B2 (pt) |
| EP (1) | EP1592683A2 (pt) |
| JP (1) | JP2006518385A (pt) |
| KR (1) | KR20050101551A (pt) |
| CN (1) | CN100422171C (pt) |
| AR (1) | AR043181A1 (pt) |
| AU (1) | AU2004213374A1 (pt) |
| BR (1) | BRPI0407253A (pt) |
| CA (1) | CA2515570A1 (pt) |
| CO (1) | CO5650164A2 (pt) |
| CR (1) | CR7930A (pt) |
| EC (1) | ECSP055964A (pt) |
| MX (1) | MXPA05008438A (pt) |
| NO (1) | NO20053792L (pt) |
| NZ (1) | NZ541699A (pt) |
| PL (1) | PL378120A1 (pt) |
| RU (1) | RU2347780C2 (pt) |
| TW (1) | TW200505904A (pt) |
| UA (1) | UA80184C2 (pt) |
| WO (1) | WO2004074243A2 (pt) |
| ZA (1) | ZA200506416B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1293072C (zh) * | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5－羟色胺－6配体的杂环基氧基－、－硫代－和－氨基吲哚衍生物 |
| AU2002309585B2 (en) * | 2001-04-20 | 2008-01-31 | Wyeth | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| WO2007032833A1 (en) * | 2005-08-15 | 2007-03-22 | Wyeth | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| NZ565872A (en) * | 2005-08-15 | 2011-06-30 | Wyeth Corp | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN101370775A (zh) * | 2006-01-13 | 2009-02-18 | 惠氏公司 | 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CN101437519A (zh) * | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| EP2001865A1 (en) * | 2006-04-05 | 2008-12-17 | Wyeth a Corporation of the State of Delaware | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| ATE509636T1 (de) * | 2006-06-23 | 2011-06-15 | Esteve Labor Dr | Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität |
| US7939520B2 (en) | 2007-05-15 | 2011-05-10 | Wyeth Llc | Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2009155399A1 (en) * | 2008-06-20 | 2009-12-23 | Wyeth | 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| WO2010124042A2 (en) * | 2009-04-23 | 2010-10-28 | Abbott Laboratories | Modulators of 5-ht receptors and methods of use thereof |
| CA2953004C (en) | 2014-07-08 | 2023-02-21 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| AU2015341913B2 (en) * | 2014-11-03 | 2020-07-16 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN104693186B (zh) * | 2014-12-31 | 2017-12-22 | 青岛黄海制药有限责任公司 | 一种吲哚衍生物中c‑f键生成c‑n键合成西泮类药物的方法 |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| US11787780B2 (en) | 2020-06-22 | 2023-10-17 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| US12098144B2 (en) | 2021-12-21 | 2024-09-24 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
| IL313667A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Glucocorticoid receptor antagonists INDAZOL CYCLES |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ230045A (en) * | 1988-08-05 | 1990-11-27 | Janssen Pharmaceutica Nv | 3-piperazinylbenzazole derivatives and pharmaceutical compositions |
| AR008245A1 (es) * | 1996-06-21 | 1999-12-29 | Glaxo Group Ltd | Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados |
| US6391872B1 (en) | 1997-11-04 | 2002-05-21 | Pfizer Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
| EP2298738B1 (en) * | 2000-11-02 | 2012-09-19 | Wyeth LLC | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| JP4307073B2 (ja) * | 2000-12-22 | 2009-08-05 | ワイス | ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物 |
| MXPA03005433A (es) * | 2000-12-22 | 2003-09-10 | Wyeth Corp | Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6. |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| AU2002309585B2 (en) * | 2001-04-20 | 2008-01-31 | Wyeth | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN1293072C (zh) * | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5－羟色胺－6配体的杂环基氧基－、－硫代－和－氨基吲哚衍生物 |
| US7199147B2 (en) * | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| JP2005527463A (ja) | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| US20050124626A1 (en) | 2002-03-27 | 2005-06-09 | Johnson Christopher N. | Novel compounds |
| ES2386828T3 (es) | 2002-03-27 | 2012-08-31 | Glaxo Group Limited | Derivados de quinolina y su uso como ligandos 5-HT6 |
| TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| AU2004213375A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands |
| DE102004046356A1 (de) * | 2004-09-24 | 2006-03-30 | Clariant Gmbh | Verfahren zur Herstellung von Alk(en)ylphosphorsäureestersalzen |
-
2004
- 2004-02-10 BR BR0407253-7A patent/BRPI0407253A/pt not_active IP Right Cessation
- 2004-02-10 CA CA002515570A patent/CA2515570A1/en not_active Abandoned
- 2004-02-10 KR KR1020057014910A patent/KR20050101551A/ko not_active Ceased
- 2004-02-10 PL PL378120A patent/PL378120A1/pl unknown
- 2004-02-10 WO PCT/US2004/003926 patent/WO2004074243A2/en not_active Ceased
- 2004-02-10 TW TW093103031A patent/TW200505904A/zh unknown
- 2004-02-10 EP EP04709911A patent/EP1592683A2/en not_active Withdrawn
- 2004-02-10 AU AU2004213374A patent/AU2004213374A1/en not_active Abandoned
- 2004-02-10 JP JP2006503466A patent/JP2006518385A/ja not_active Ceased
- 2004-02-10 MX MXPA05008438A patent/MXPA05008438A/es active IP Right Grant
- 2004-02-10 NZ NZ541699A patent/NZ541699A/en unknown
- 2004-02-10 CN CNB2004800094268A patent/CN100422171C/zh not_active Expired - Fee Related
- 2004-02-10 RU RU2005128556/04A patent/RU2347780C2/ru active
- 2004-02-13 US US10/778,427 patent/US7238696B2/en not_active Expired - Fee Related
- 2004-02-13 AR ARP040100459A patent/AR043181A1/es unknown
- 2004-10-02 UA UAA200508735A patent/UA80184C2/uk unknown
-
2005
- 2005-08-03 CR CR7930A patent/CR7930A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079298A patent/CO5650164A2/es not_active Application Discontinuation
- 2005-08-10 NO NO20053792A patent/NO20053792L/no not_active Application Discontinuation
- 2005-08-11 EC EC2005005964A patent/ECSP055964A/es unknown
- 2005-08-11 ZA ZA200506416A patent/ZA200506416B/xx unknown
-
2007
- 2007-05-15 US US11/803,531 patent/US7560470B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 US US12/483,344 patent/US20090253711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05008438A (es) | 2005-10-19 |
| JP2006518385A (ja) | 2006-08-10 |
| ECSP055964A (es) | 2006-01-16 |
| CN1771244A (zh) | 2006-05-10 |
| CO5650164A2 (es) | 2006-06-30 |
| CR7930A (es) | 2006-02-07 |
| US20090253711A1 (en) | 2009-10-08 |
| TW200505904A (en) | 2005-02-16 |
| CN100422171C (zh) | 2008-10-01 |
| AR043181A1 (es) | 2005-07-20 |
| US7238696B2 (en) | 2007-07-03 |
| WO2004074243A2 (en) | 2004-09-02 |
| AU2004213374A1 (en) | 2004-09-02 |
| WO2004074243A3 (en) | 2004-12-02 |
| RU2347780C2 (ru) | 2009-02-27 |
| NZ541699A (en) | 2009-01-31 |
| PL378120A1 (pl) | 2006-03-06 |
| CA2515570A1 (en) | 2004-09-02 |
| BRPI0407253A (pt) | 2006-01-31 |
| US20070232618A1 (en) | 2007-10-04 |
| US7560470B2 (en) | 2009-07-14 |
| ZA200506416B (en) | 2007-02-28 |
| EP1592683A2 (en) | 2005-11-09 |
| KR20050101551A (ko) | 2005-10-24 |
| RU2005128556A (ru) | 2006-01-27 |
| UA80184C2 (en) | 2007-08-27 |
| US20040167122A1 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053792L (no) | Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander | |
| NO20044763L (no) | 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander | |
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20060230L (no) | Nye aminobenzofenonforbindelser | |
| NO20044764L (no) | 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| NO20055731L (no) | Cannabinoide reseptorligander og deres anvendelse | |
| NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
| NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
| WO2002051837A3 (en) | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| ATE457313T1 (de) | Bicyclische heterocyclische p-38-kinase- inhibitoren | |
| NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20063787L (no) | Terapeutiske preparater | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| NO20065984L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
| NO20072461L (no) | Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme | |
| BRPI0410905A (pt) | inibidores de p-38 | |
| NO20070247L (no) | Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase | |
| MXPA04005886A (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6. | |
| ATE520668T1 (de) | Sigmarezeptor-inhibitoren | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |